Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript Summary
Financing expenses for the first nine months of 2024 were approximately $0.38 million, a shift from a financing income of $2.3 million in the first nine months of 2023.The following is a summary of the Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript:
以下是Evogene Ltd. (EVGN) 2024年第三季度业绩会议记录摘要：
Financial Performance:
财务表现：
Evogene reported Q3 2024 revenues of approximately $1.8 million, a decrease from Q3 2023's $3.8 million, primarily due to a decrease in licensing revenue from Lavie Bio.
The company recorded an operating loss of approximately $17.6 million in the first nine months of 2024, slightly improved from $18.9 million in the same period of 2023.
Financing expenses for the first nine months of 2024 were approximately $0.38 million, a shift from a financing income of $2.3 million in the first nine months of 2023.
Projected cash usage for 2024 is approximately $8 million to $10 million, a decrease from $12.5 million in 2023, following a reduction in workforce by 16% and other expense management strategies.
Evogene报告2024年第三季度约180万美元的营业收入，较2023年第三季度的380万美元下降，主要是由于Lavie Bio的许可收入减少。
公司在2024年前九个月录得约1760万美元的营业亏损，略有改善，较2023年同期的1890万美元有所降低。
2024年前九个月的融资费用约为38万美元，相比于2023年前九个月的230万美元的融资收入有所变动。
2024年的预计现金使用额约为800万至1000万美元，较2023年的1250万美元有所下降，此前通过削减16%的员工和其他费用管理策略实现。
Business Progress:
业务进展：
Evogene highlighted significant progress in seed production infrastructure notably in Kenya and Brazil for its subsidiary Casterra, which will support existing and future seed demands.
Lavie Bio announced the expansion of its bio-inoculant product, Yalos, to winter wheat and soybeans, and advancement of its bio-fungicide LAV321.
The company announced a collaboration with Google Cloud to develop a generative AI model for novel small molecule design, leveraging Evogene's AI tech engines.
Evogene在肯尼亚和巴西的子公司Casterra显著加强了种子生产制造业务，将支持现有和未来的种子需求。
Lavie Bio宣布将其生物接种剂产品Yalos扩展到冬小麦和大豆，并推进其生物杀菌剂LAV321的研发。
该公司宣布与Google Cloud合作，开发一个用于新型小分子设计的生成式人工智能模型，利用Evogene的人工智能技术引擎。
Opportunities:
机会：
Continued revenue growth anticipated for 2024, driven by existing seed orders from Casterra and new product launches from Lavie Bio.
Expansion into bioinformatics through collaboration with Google Cloud, positioning its AI tech engines at the forefront of novel molecule design.
预计2024年营业收入将继续增长，主要受Casterra的现有种子订单和Lavie Bio的新产品推出的推动。
通过与Google Cloud合作，扩展至生物信息学领域，将其人工智能技术引擎定位于新型分子设计的最前沿。
Risks:
风险：
Fluctuations in operating expenses and increased financial expenses related to warrants issued during fundraising could impact financial stability.
营业费用波动和与筹集资金期间发行的认股权证相关的增加的财务费用可能会影响财务稳定性。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
